Orion Corporation completed share acquisitions

ORION CORPORATION        
STOCK EXCHANGE RELEASE
4 NOVEMBER 2022 at 18.35 EET             

Orion Corporation completed share acquisitions

The share acquisitions introduced by Orion Corporation on 25 August 2022 have been completed. The Company has bought throughout the time interval from 1 September 2022 to 4 November 2022 by way of buying and selling on regulated market organised by Nasdaq Helsinki Oy a complete of 400,000 Company’s personal B shares at a median value per share of roughly EUR 44.7956. The whole buy value paid for the shares was EUR 17,918,232.27.

After the repurchases, the Company holds a complete of 932,771 personal B shares equivalent to roughly 0.66% of the full variety of the shares and 0.12% of the votes.
  

Orion Corporation

                        
                        
Contact particular person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054 

Publisher: 
Orion Corporation 
Communications 
Orionintie 1A, FI-02200 Espoo, Finland 
https://www.orion.fi/en  
https://www.twitter.com/OrionCorpIR 

Orion is a globally working Finnish pharmaceutical firm – a builder of well-being. Orion develops, manufactures and markets human and veterinary prescription drugs and lively pharmaceutical substances. The firm is constantly creating new medication and therapy strategies. The core remedy areas of Orion’s pharmaceutical R&D are oncology and ache. Orion’s web gross sales in 2021 amounted to EUR 1,041 million and the corporate had about 3,350 staff on the finish of the 12 months. Orion’s A and B shares are listed on Nasdaq Helsinki.